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673conventional 2-dimensional echocardiography is a poor quan-
titative measure of the RV and is relatively expensive (10–14).
There are recommended electrocardiographic (ECG)
criteria for RVH, which could provide a noninvasive, well-
tolerated, inexpensive method of screening (15–20).
However, these criteria were derived from cadaveric dissec-
tion of selected patients in studies performed over a genera-
tion ago and have never been validated. Historically, studies
of ECG criteria for right, left, or bilateral ventricular
hypertrophy were small in size, were limited to white pop-
ulations, and (with rare exception) (17,21) attempted to ﬁnd
ECG correlates of RV pathology in patients with previously
diagnosed, clinically advanced cardiopulmonary disease
(16,18,19,22–27) Therefore, ECG criteria for RVH have
unclear accuracy in a community-based adult population
without known cardiovascular disease (28,29).
RV structure and function are difﬁcult to assess with
standard transthoracic echocardiography, and although
newer research techniques, such as 3-dimensional echocar-
diography (12,30–35) and speckle tracking (36–43), over-
come some of these limitations, cardiac magnetic resonance
imaging (cMRI) accurately measures RV mass without
requiring any assumptions about RV morphology. We have
previously established normative allometric equations to
deﬁne RVH as RV mass >95th percentile based on
demographics and body size in a normal population, which
is generally mild (44). In this study, we aimed to address
whether the American Heart Association (AHA) criteria for
RVH (15) apply to RVH detected by cMRI in a large,
population-based, multiethnic sample of adults in the
community.
Methods
MESA (Multi-Ethnic Study of Atherosclerosis) is a multi-
center, prospective cohort study designed to investigate the
prevalence, correlates, and progression of subclini-
cal cardiovascular disease in Caucasians, African Americans,
Hispanics, and Asian Americans without clinical cardiovas-
cular disease at baseline (45). In 2000 to 2002, MESA
recruited 6,814 men and women, 45 to 84 years of age, from 6
U.S. communities: Forsyth County, North Carolina;
Northern Manhattan and the Bronx, New York; Baltimore
City and Baltimore County, Maryland; St. Paul, Minnesota;
Chicago, Illinois; and Los Angeles, California. All patients
gave informed consent for participation inMESA. Exclusion
criteria included clinical cardiovascular disease (physician-
diagnosed heart attack, stroke, transient ischemic attack, heart
failure, angina, current atrial ﬁbrillation, any cardiovascular
procedure), weight >136 kg (300 lb), pregnancy, or impedi-
ment to long-term participation. By design, patients with
hypertension, diabetes mellitus, and hypercholesterolemia
were included as these conditions were not considered clinical
cardiovascular disease. Of the 6,814 MESA participants,
5,098 (75%) had cMRIs; 5,004 (73%) were interpretable for
left ventricular (LV) measures. MESA–RV (Multi-EthnicStudy of Atherosclerosis–Right
Ventricle Study) is an ancillary
study that attempted to read
4,484 (66%) cMRIs, of which
4,204 (62%) were available and
interpretable for RVmorphology.
The total number of cMRIs
with RV interpretation was limi-
ted by grant funding; however,
a sufﬁcient number of scans were
interpreted to provide enough
power to achieve our aims. We
sampled the MESA population
without regard to demographics
or other participant features.
Thirty-ﬁve participants (<1%)
were excluded for lack of ECG
data, leaving 4,169 (61%) (Fig. 1).
We also excluded 107 participants
(1.6%) with interventricular con-
duction delay, left bundle branch block, Wolff-Parkinson-
White syndrome, advanced atrioventricular block, and/or
poor-quality ECGs (which were not exclusive), leaving
4,062 (60%) in the study sample.
The protocols of MESA and all studies described herein
were approved by the Institutional Review Boards of all
collaborating institutions and the National Heart, Lung, and
Blood Institute. The National Heart, Lung, and Blood
Institute staff participated in the design of MESA.
cMRI measures. The MESA cMRI protocol, image
analysis, and methods for interpretation of LV and RV
parameters have been previously reported (46–49). Brieﬂy,
cMRI examinations were transmitted to the reading center
at Johns Hopkins University in Baltimore, Maryland, with
the digital imaging and communications in medicine
transfer protocol. Image analysis was performed by 2 expe-
rienced readers on Windows (Microsoft, Seattle, Wash-
ington) workstations with QMASS software (version 4.2,
Medis, Leiden, the Netherlands).
The endocardial and epicardial borders of the RV were
traced manually on the short-axis cine images at the end-
systolic and -diastolic phases. Full visualization of the
correct placement of RV contours relied on evaluation of
cine images to determine the demarcation between the right
atrium and the RV. Contours were modiﬁed at basal slices
of the heart by careful identiﬁcation of the tricuspid valve so
as to exclude the right atrium and to avoid overestimation
of the volumes. Papillary muscles and trabeculae were in-
cluded in the RV volumes and excluded from RV mass, as is
commonly done for LV mass (50,51). RV mass was mea-
sured as the sum of the myocardial area (the difference
between endocardial and epicardial contours) times slice
thickness plus image gap in the end-diastolic phase multi-
plied by the speciﬁc gravity of the myocardium (1.05 g/ml).
The intrareader intraclass correlation coefﬁcient from
random, blinded rereads of 229 scans for RV mass was
Figure 1 Study Population
The MESA (Multi-Ethnic Study of Atherosclerosis) cohort and ﬁnal study population. Percentages given relative to size of original MESA cohort, n ¼ 6,814. AV ¼ atrioventricular;
ECG ¼ electrocardiographic; LV ¼ left ventricle; MRI ¼ magnetic resonance imaging; RV ¼ right ventricle.
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6740.94. The inter-reader intraclass correlation coefﬁcient from
random, blinded rereads of 240 scans for RV mass was 0.89.
Electrocardiography. Standard 12-lead ECGs were digi-
tally acquired using a Marquette MAC-PC electrocardio-
graph (Marquette Electronics, Milwaukee, Wisconsin) at
10-mm/mV calibration and speed of 25 mm/s. To minimize
interindividual variability in vector detection based on elec-
trode placement, ECG technicians in MESA underwent
training in determining anatomic landmarks (i.e., the fourth
and ﬁfth intercostal spaces and left midaxillary line) and to
use an electrode locator designed to more precisely place lead
V4 at a 45 angle between the midsternal and left midaxillary
lines at the ﬁfth intercostal space. Electrodes V3 and V5 were
placed in a straight line halfway between electrodes V2 and
V4, and V4 and V6, respectively. Limb leads were placed on
the wrists and ankles. All measurements were automated,
and analysis was performed centrally at the EPICARE
reading center, Wake Forest University. Furthermore, all
ECGs were visually inspected for technical errors and
inadequate quality. The ECG criteria of RVH from the
2009 AHA Recommendations for Standardization and
Interpretation of the ECG were examined (Table 1) (15).
Independent variables and covariates. Race/ethnicity was
self-reported during the baseline MESA examination
according to 2000 U.S. Census criteria as race (Caucasian,
African American, Asian American) and ethnicity (Hispanicor non-Hispanic). Standard questionnaires were used to
ascertain smoking status (classiﬁed as never, former, or
current) and pack-years. Resting blood pressure was
measured 3 times with the Dinamap Monitor PRO 100
(Critikon, Tampa, Florida) automated oscillometric device,
and the average of the last 2 measurements was used.
Hypertension was deﬁned as systolic blood pressure 140
mm Hg, diastolic blood pressure 90 mm Hg, or self-
reported hypertension and current use of antihypertensive
medication. Presence of diabetes mellitus was based on self-
reported physician diagnosis, use of medication for hyper-
glycemia, or a fasting glucose value 126 mg/dl, the latter
measured by rate reﬂectance spectrophotometry (Johnson &
Johnson Clinical Diagnostics, Inc., Rochester, New York).
Fasting glucose between 100 and 125 mg/dl was considered
impaired fasting glucose. Fasting blood samples were drawn
and sent to a central laboratory for measurement of glucose.
Spirometric measures and lung density from computed
tomography of the chest (% emphysema) were acquired as
described (44).
Statistical analysis. Continuous variables were summarized
by mean  SD and categorical variables by n (%). We
determined the sensitivity, speciﬁcity, positive predictive
values, and negative predictive values of the 2009 AHA
ECG criteria for RVH (15). We performed the primary
analysis in those without left ventricular hypertrophy (LVH)
Table 1
American Heart Association Recommended Criteria
for Right Ventricular Hypertrophy by Study
Lewis (27), 1914
(R 1þS III) – (S IþR III) <15 mV
Myers et al. (18), 1948
Tall R V1 >6 mV
Increased R:S ratio V1 >1.0
Deep S V5 >10 mV
Deep S V6 >3 mV
Small S V1 <2 mV
Small R V5,6 <3 mV
Reduced R:S ratio V5 <0.75
Reduced R:S ratio V6 <0.4
R peak V1 (QRS duration <0.12 s) >0.035 s
Presence of QR V1
Sokolow and Lyon (26), 1949
Tall R aVR >4 mV
Reduced R:S V5 to R:S V1 <0.04
R V1 þ S V5,6 >10.5 mV
Butler et al. (19), 1986
Max R V1,2 þ max S I, aVL–S V1 >6 mV
Supportive criteria (15)
P in II 2.5 mV
S > R in I
S > R in II
S > R in III
R:S in V1 > R:S in V3,4
Presence of RSR’ in V1 (QRS >0.12 s)
Presence of T-wave inversion in V1–V3
Presence of S in I and Q in III
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675or reduced LV ejection fraction, and we performed sensi-
tivity analyses including all participants. We used classiﬁ-
cation and regression tree (CART) analysis to determine if
any combination of the criteria would perform better than
the individual criteria. We performed additional analyses of
the continuous ECG parameters from the ECG criteria
using receiver-operating characteristic curves to determine if
there may be different optimal cutoffs.
Detailed derivations of the normative equations used to
identify RVH and LVH from a healthy subset of MESA
have been published previously (44,52). Equations used for
the % predicted RV mass were as follows: for men, RV
mass/(10.59 $ age–0.320Ht1.135Wt0.315); and for women, RV
mass/(11.25 $ age–0.320Ht1.135Wt0.315), where Ht is height
in meters and Wt is weight in kg. We deﬁned RVH as
present if RV mass was >126% predicted (95th percentile),
which included mild RVH. We performed additional
analyses with RVH deﬁned as RV mass >99th percentile.
Results
The study sample for the primary analysis with normal LV
morphology and function (n ¼ 3,719) was 61.3  10.0 years
of age, 46.5% male, 39.6% Caucasian, 25.5% African
American, 21.9% Hispanic, and 13.0% Asian (Table 2). The
mean body mass index was 27.9  5.0 kg/m2. Participants
with LVH or decreased LV ejection fraction were morelikely to be male, to be African American, to have hyper-
tension and diabetes, and to be current smokers, and were
less likely to be Asian American or college graduates. Age,
body mass index, and height were similar between groups;
formal statistical testing is not appropriate for such
comparisons, which are descriptive rather than inferential
(53). Using sex-speciﬁc normative equations, the overall
prevalence of RVH in the entire study group was 7.2% (RV
mass in RVH: 27.3  4.6 g vs. RV mass with no RVH: 20.5
 4.0 g; 6.0% of participants with normal LV morphology
had RVH and 19.5% of participants with LVH or decreased
LV function had RVH). Characteristics of those with and
without RVH are shown in Table 3.
In participants with normal LV morphology, the majority
of ECG criteria for RVH had sensitivities <10% (Table 4).
The Lewis criterion from 1914 [(R in lead I þ S in lead
III) – (S in lead 1 þ R in lead III) <15 mV] had the highest
sensitivity (80.4%), but also the lowest speciﬁcity of all of
the criteria. Similarly, the “supportive criterion” of S >R in
lead III had a sensitivity of 56.7%, but a speciﬁcity of only
46.1%. Although other ﬁndings were speciﬁc, the prevalence
of RVH was sufﬁciently low that the post-test probability of
RVH was not signiﬁcantly different than the pre-test
probability even with the presence of the ECG sign. For
example, although having an R-peak in V1 >0.035 s with
a QRS <0.12 s had a positive predictive value of 12.0%
(95% conﬁdence interval: 5.9% to 21.0%), this was not
much different from the pre-test probability of RVH (6%),
and the conﬁdence interval included the pre-test probability.
Similarly, with negative predictive values of approximately
94% for all ECG criteria, an ECG negative for all AHA
criteria for RVH did not signiﬁcantly alter the pre-test
probability for RVH given its low prevalence in this pop-
ulation. CART analysis failed to identify any combination
of the previous criteria that was better than the criteria
used singly.
We attempted to deﬁne new criteria by ﬁnding optimal
cut points for each wave amplitude. However, the areas
under the curves (AUCs) for all wave amplitudes (modeled
as continuous variables) were uniformly low in the main
study sample (all AUCs 0.55). Furthermore, CART
analysis was used to explore the relationships between a
combination of the individual wave amplitudes and RVH.
There was no combination of the wave variables that was
better than the criteria used singly.
The sensitivity, speciﬁcity, positive and negative predic-
tive values, and AUCs were essentially unchanged after
including patients with LVH and reduced LV ejection
fraction (and a higher prevalence of RVH; data not shown).
None of the results differed based on age, sex, race, or
smoking. Potential cutoffs for mild, moderate, and severe
RVH could be as follows: mild RVH >95th percentile
and 97th percentile, moderate RVH >97th percentile
and 99th percentile, and severe RVH >99th percen-
tile. We performed additional analyses using severe RVH,
which was present in 1% of the study sample (RV mass in
Table 2 Characteristics of Study Sample
Normal LV
(n ¼ 3,719)
LVH or
Reduced LVEF
(n ¼ 343)
All
(n ¼ 4,062)
Age, yrs 61.3  10.0 63.3  10.2 61.4  10.1
Male 46.5 51.3 46.9
Race
Caucasian 39.6 28.6 38.7
Asian 13.0 7.6 12.5
African American 25.5 36.7 26.4
Hispanic 21.9 27.1 22.3
Education
Some high school 16.4 18.5 16.5
High school/GED 18.1 24.1 18.6
Some college (more than high school) 28.6 25.9 28.3
Bachelor’s degree 18.2 12.9 17.8
Graduate degree 18.7 18.5 18.7
BMI, kg/m2 27.9  5.0 28.0  4.8 27.9  5.0
Hypertension 40.4 67.1 42.6
Diabetes mellitus
Normal 76.2 65.3 75.3
Impaired fasting glucose 13.0 16.0 13.2
Diabetes 10.9 18.7 11.5
Smoking status
Never 52.6 43.8 51.9
Former 35.6 35.6 35.6
Current 11.8 20.6 12.5
Pack-years, among ever-smokers 10.7  23.2 12.2  19.1 10.8  22.9
RV measures
RV mass, g 20.9  4.3 22.7  4.8 21.0  4.4
RV hypertrophy 6.0 19.5 7.2
RV ejection fraction 70.6  6.3 69.4  7.4 70.5  6.4
LV measures
LV mass, g 140.1  34.1 196.8  43.7 144.9  38.4
LVEF 69.6  6.6 63.4  11.3 69.1  7.3
Values are mean  SD or %.
BMI ¼ body mass index; LV ¼ left ventricular; LVEF ¼ left ventricular ejection fraction; LVH ¼ left ventricular hypertrophy; RV ¼ right ventricular.
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676severe RVH: 30.2  5.7 g vs. RV mass without severe RVH:
20.9  4.3 g). Performance of the ECG criteria was no
better with this more extreme deﬁnition of RVH (the best
criterion had positive predictive value 6.7%; 95% CI: 0.2% to
32.0%).
Discussion
We have shown that the 2009 AHA recommended ECG
criteria for RVH have inadequate sensitivity and speciﬁcity
in a community-based multiethnic sample of adults without
clinical cardiovascular disease and should not be used to
screen for mild RVH in this population. Most criteria
(including R in lead V1 >6 mV, S in lead V5 >10 mV, R in
lead V1 þ S in lead V5,6 >10.5 mV, and presence of a QR in
lead V1) indicatedw10% chance of having RVH, which was
not much different from the underlying prevalence of RVH
in our study sample and, therefore, would not be helpful
clinically. Primary analyses were performed in those partic-
ipants with normal LV morphology; conclusions weresimilar after including those with LVH or focusing on those
with more severe RVH.
Current recommended AHA criteria for RVH by surface
ECG are based on older studies with small study pop-
ulations and spectra of disease that may not be pertinent in
the modern era in the United States (15–20). The test
properties of ECG in populations with severe RVH from
advanced cardiopulmonary disease are likely not applicable
to an asymptomatic outpatient population undergoing
routine testing for screening. Ten of 15 screening criteria for
RVH were from a single study of 40 patients found to have
RVH at autopsy due to cor pulmonale (24), mitral stenosis
(13), Tetralogy of Fallot (2), or “arteriovenous aneurysm”
(18). Although speciﬁcity was high, measured criteria were
insensitive. Furthermore, the determination of RVH was
nonstandard (17). Lewis (27) performed an autopsy study
of 33 patients with mitral stenosis (including 17 with
concomitant aortic valve disease) revealing that 50%
demonstrated the “Einthoven’s Sign” (54,55), [(RI þ SIII) –
(SI þ RIII) <15 mV]. The preponderance of mitral stenosis
Table 3 Characteristics of Study Participants With and Without RVH
All Subjects Normal LV
RVH
(n ¼ 291)
Normal RV
(n ¼ 3,771) p Value
RVH
(n ¼ 224)
Normal RV
(n ¼ 3,495) p Value
Age, yrs 63.5  10.4 61.3  10.0 0.0004 63.3  10.4 61.1  10.0 0.002
Male 43.3 47.2 0.20 42.0 46.8 0.16
Race
Caucasian 42.3 38.4 0.01 43.3 39.4 0.18
Asian 8.6 12.8 9.8 13.2
African American 22.0 26.8 21.9 25.7
Hispanic 27.1 22.0 25.0 21.7
Education
Some high school 20.0 16.3 0.15 19.3 16.2 0.39
High school/GED 21.1 18.5 20.6 18.0
Some college (more than high school) 27.2 28.4 27.4 28.6
Bachelor’s degree 13.4 18.1 14.3 18.5
Graduate degree 18.3 18.7 18.4 18.7
BMI, kg/m2 28.2  5.3 27.9  5.0 0.29 28.2  5.3 27.8  5.0 0.29
Hypertension 48.1 42.2 0.05 43.8 40.1 0.29
Diabetes mellitus
Normal 74.2 75.3 0.76 77.2 76.1 0.38
Impaired fasting glucose 12.4 13.3 9.8 13.2
Diabetes 13.4 11.4 12.9 10.8
Smoking status
Never 53.4 51.8 0.62 55.6 52.5 0.55
Former 35.9 35.6 34.5 35.7
Current 10.7 12.6 9.9 11.9
Pack-years, among ever-smokers 11.8  21.8 10.8  22.9 0.91 11.4  21.0 10.7  23.3 0.86
FVC, ml 3,141  974
(n ¼ 159)
3,223  953
(n ¼ 2,500)
0.24 3,141  982
(n ¼ 130)
3,231  952
(n ¼ 2,356)
0.31
% Predicted FVC 96.7  16.8
(n ¼ 159)
96.1  15.8
(n ¼ 2,500)
0.91 97.1  16.7
(n ¼ 130)
96.3  15.7
(n ¼ 2,356)
0.70
FEV1/FVC ratio 0.8  0.1
(n ¼ 159)
0.8  0.1
(n ¼ 2,498)
0.49 0.8  0.1
(n ¼ 130)
0.8  0.1
(n ¼ 2,355)
0.48
FEV1/FVC <0.7 20.1
(n ¼ 159)
21.9
(n ¼ 2,498)
0.61 20.0
(n ¼ 130)
21.4
(n ¼ 2,355)
0.70
Emphysema by CT, % 14.5
(n ¼ 162)
17.2
(n ¼ 2,569)
0.01 14.9
(n ¼ 132)
17.3
(n ¼ 2,417)
0.03
Asthma, self-reported 10.0 9.4 0.5 9.8 9.2 0.26
RV measures
RV mass, g 27.3  4.6 20.5  4.0 <0.0001 27.2  4.7 20.5  4.0 <0.0001
RV ejection fraction, % 69.5  6.5 70.6  6.4 0.02 69.3  6.6 70.7  6.3 0.01
LV measures
LV mass, g 161.3  44.9 143.7  37.5 <0.0001 148.5  32.8 139.6  34.1 0.0002
LV ejection fraction, % 68.6  6.9 69.1  7.3 0.32 69.3  6.3 69.6  6.6 0.67
Values are mean  SD or %.
FEV1 ¼ forced expiratory volume in 1 s; FVC ¼ forced vital capacity; RVH ¼ right ventricular hypertrophy; other abbreviations as in Table 2.
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677and aortic valve lesions make the ECG ﬁndings difﬁcult to
apply to the general population, including that of MESA,
where the positive and negative predictive values of this sign
were poor.
Sokolow and Lyon (26) studied the presence of an
R-wave in aVR >4 mV, reduced R:S in V5 to R:S in V1,
and R-wave in V1 þ S-wave in V5,6 >10.5 mV in 60
clinically-ill patients (1 month to 70 years of age, 40%
were <5 years of age) with cyanotic congenital heart disease
(n ¼ 44), chronic obstructive pulmonary disease (n ¼ 8),
mitral stenosis (n ¼ 6), kyphoscoliosis (n ¼ 1), orpulmonary ﬁbrosis (n ¼ 1) and 150 healthy controls.
Diagnoses of RVH were made by autopsy or surgery in 18
patients with congenital heart disease and by angiocardio-
gram in 1. An R-wave >4 mV in aVR had a positive
predictive value of >30%, which was much higher than that
found in our study sample.
Another study included 50 patients with RVH due to
mitral stenosis and 500 healthy controls (19). Hypothesizing
that the sum of the anterior, rightward, and posterolateral
depolarization forces would be greater in RVH compared with
controls, these investigators found that the combination of
Table 4
Sensitivity, Speciﬁcity, PPV, and NPV for AHA Criteria for Right Ventricular Hypertrophy in Participants With
Normal Left Ventricular Morphology
Author (Ref. #), Year Criterion Sensitivity (95% CI) Speciﬁcity (95% CI) PPV (95% CI) NPV (95% CI)
Lewis (27), 1914
(R 1þS III)–(S IþR III) <15 mV 80.4 (75.2–85.6) 16.8 (15.6–18.0) 5.8 (5.0–6.7) 93.0 (90.8–94.9)
Myers et al. (18), 1948
R V1 >6 mV 1.8 (0.1–3.5) 98.8 (98.4–99.1) 8.5 (2.4–20.4) 94.0 (93.2–94.8)
R:S V1 >1 0.9 (0.0–2.2) 97.6 (97.1–98.2) 2.5 (0.3–8.7) 93.8 (92.9–94.6)
S V5 >10 mV 0.5 (0.0–1.3) 99.6 (99.4–99.8) 6.3 (1.6–30.2) 94.0 (93.2–94.7)
S V6 >3 mV 2.2 (0.3–4.2) 96.3 (95.7–96.9) 3.7 (1.2–8.5) 93.9 (93.1–94.7)
S V1 <2 mV 7.6 (4.1–11.6) 91.4 (90.5–92.4) 5.4 (3.2–8.4) 93.9 (93.1–94.7)
R V5 <3 mV d d d d
R V6 <3 mV 0.5 (0.0–1.3) 99.5 (99.2–99.7) 5.0 (0.0–25.9) 94.0 (93.2–94.7)
R:S V5 <0.75 d d d d
R:S V6 <0.4 d d d d
R peak V1 (QRS <.12 s) >0.035 s 4.5 (1.8–7.2) 97.9 (97.4–98.4) 12.0 (5.9–21.0) 94.1 (93.3–94.9)
QR V1 1.3 (0.0–2.8) 99.1 (98.7–99.4) 8.3 (1.8–22.4) 94.0 (93.2–94.7)
Sokolow and Lyon (26), 1949
R aVR >4 mV 0.5 (0.0–1.3) 99.8 (99.6–99.9) 11.1 (2.8–48.2) 94.0 (93.2–94.7)
R:S V5/R:S V1 <0.04 d d d d
R V1 þ S V5 >10.5 mV 1.3 (0.0,2.8) 98.8 (98.4–99.2) 6.7 (1.4–18.3) 94.0 (93.2–94.7)
R V1 þ S V6 >10.5 mV 0.9 (0.0–2.1) 99.5 (99.2–99.7) 9.5 (1.2–30.4) 94.0 (93.2–94.7)
Butler et al. (19), 1986
(Max R V1,2) þ (Max S I–aVL) – S V1 >6 mV 12.5 (8.2–16.8) 85.3 (84.2–86.5) 5.2 (3.5–7.4) 93.8 (92.9–94.6)
AHA ¼ American Heart Association; CI ¼ conﬁdence interval; NPV ¼ negative predictive value; PPV ¼ positive predictive value; d ¼ estimate could not be derived in the cohort.
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678[(maximum of R-wave in V1 or V2) þ (maximum of S-wave
in I or aVL) – (S-wave in V1)] 0.7 mV and an R-wave in
I 0.2 mV provided a speciﬁcity of 94% and sensitivity of
66%, both more sensitive and speciﬁc than in the MESA
population. These patients were an average of 45 years of age,
88% were female, and all had known clinically-diagnosed
valvular disease. In patients with known isolated RVH or
biventricular hypertrophy, this criterion was found to be
comparably speciﬁc but insensitive (16). A more recent study
compared this same criterion to the gold standard of cMRI in
28 patients with known pulmonary arterial hypertension and
conﬁrmed high speciﬁcity but with similarly low sensitivities
of 64% to 71%, depending on the deﬁnition of RVH used
(56).
Several recent studies have aimed to examine the useful-
ness of ECG in the diagnosis of RVH as measured by cMRI
(56–58) or elevated pulmonary arterial pressures (59).
Uniformly, in much smaller groups of patients (ranging from
n ¼ 23 to n ¼ 38) than our study, various criteria for RVH
have been examined, including the AHA recommended
criteria. Similar to prior published work, these studies were
in patients with known RVH (56–58) or, based on clinical
risk factors, who were at high risk for pulmonary hyper-
tension (59). Investigators found low sensitivity and insuf-
ﬁcient speciﬁcity to be clearly useful in identifying RVH.
Furthermore, the question of whether changing cutoff values
for criteria would be helpful has been raised (57), which our
study demonstrates as ineffective in a large, multiethnic
population. In a population of 216 individuals at high risk
for pulmonary hypertension, Scherptong et al. (59) founda relationship between ventricular gradient (difference in
averaged QRS integral and T-wave integral across a 10-s
12-lead ECG) and pulmonary arterial systolic pressures,
but this study did not examine RVH.
Interestingly, the AHA criteria for RVH do not include
right axis deviation of the QRS complex. The LV mass is
much greater than that of the RV and is thought to domi-
nate the vector of ventricular activation, both in patients
with LVH and in those with normal hearts. Although
hypertrophy of the RV causes displacement of the QRS
anteriorly (as seen in the precordial leads) and to the right (as
seen in the limb leads), it is thought that marked RVH is
required to upset the normal QRS axis. For this reason, right
axis deviation is excluded from the AHA recommended
criteria for RVH screening (15).
In diagnosing other diseases of the heart affecting cardiac
function or predicting cardiovascular events, ECG has vari-
able performance as a screening tool. Use of ECG as
screening in subclinical or stable coronary artery disease is
insufﬁcient in sensitivity and is not recommended as a
screening tool for atherosclerosis (60). Nonetheless, the U.S.
Preventive Services Task Force has summarized a wealth
of large cohort studies on the utility of resting screening
ECG as a predictor of cardiovascular events, with regard to
ST-segment abnormalities, T-wave abnormalities, ST- or
T-wave abnormalities, evidence of LVH, bundle branch
blocks, and left axis deviation (61). Pooled risk estimates of
over 30 published studies revealed ST abnormalities (62–66)
and ST- or T-wave abnormalities (64,67–72) as the best
predictors of future cardiovascular events on screening ECG
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679(each with pooled hazard ratio of 1.9). Other resting ECG
characteristics such as prolonged QT interval (66,73,74),
presence of atrial ﬁbrillation (75), and right axis deviation (76)
have demonstrated inconsistent results or remain insufﬁ-
ciently studied to support formal recommendations for clin-
ical use as screening tools (61). More recently, ECG has been
shown to have low sensitivity but high speciﬁcity in diag-
nosing cMRI-deﬁned LVH, with greater sensitivity in
African Americans, and several LVH criteria predict incident
cardiovascular events (77). No prior large cohort studies have
examined the utility of ECG in screening for RVH, whether
as a diagnostic or prognostic test.
Based on our results, the 2009 AHA criteria should not
be used to screen for RVH in community-based multiethnic
studies of adults without known clinical cardiovascular
disease. Absence of the criteria does not exclude the possi-
bility of RVH and pulmonary hypertension, and RVH will
only be present in 1 of 10 individuals who fulﬁll some of the
criteria. This is likely attributable in part to the mostly mild
RVH seen in this population, even in those on the extreme
end of the spectrum of adults. Commencing a workup in
clinical cardiovascular disease-free adults similar to the
MESA population with ECG criteria for RVH can not be
recommended considering the poor predictive value, the
expense of cardiac imaging, the potential distress caused by
a spurious diagnosis of RVH (which will not be present in
90% of those who meet criteria) or pulmonary hypertension,
the unclear individual prognostic implications, and lack of
proven management strategies. In a clinically ill population,
or one at increased risk for RVH, the AHA criteria may
have clinical or prognostic utility. Furthermore, these ECG
ﬁndings in a patient presenting acutely with symptoms or
with known cardiovascular disease may have distinct impli-
cations; the ﬁndings of this study may not apply to such
populations.
Study limitations. By design of the parent study, the study
population was free of clinically-diagnosed cardiovascular
disease (but included participants with hypertension, dia-
betes, and hypercholesterolemia, which were not consid-
ered clinical heart disease). The exclusion of individuals
with clinically-diagnosed heart disease likely selected for
those with milder degrees of RVH than may be seen in the
general population (spectrum bias). However, the clinical
usefulness of screening ECG would be precisely in indi-
viduals without a previous diagnosis of signiﬁcant cardiac
disease, making our conclusions more relevant to the
population of interest. We deﬁned RVH as the 95th
percentile of the indexed RV mass, which is associated
with an increase in heart failure and cardiovascular death,
validating its use in this study (8). The test properties
of the ECG screening criteria were similar when using
a more extreme RVH deﬁnition. Last, ECG ﬁndings could
not be compared with echocardiography, which was not
performed. However, traditional transthoracic echocardi-
ography is less accurate for the diagnosis of RVH than
cMRI.Conclusions
The recommended ECG criteria for RVH are inadequate
for use as a screening tool in multiethnic adults 45 to 84
years of age without clinical cardiovascular disease.
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